12:04 PM EDT, 03/22/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) and Daiichi Sankyo Europe said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted positive opinions for the label update of Nilemdo and Nustendi.

The committee is recommending their approval as treatments to reduce low-density lipoprotein cholesterol and cardiovascular risk, the companies said.

The European Commission will now review the committee's recommendation and is expected to reach a final decision in the first half of 2024, they said.

Price: 2.21, Change: +0.10, Percent Change: +4.74